Inventor · disambiguated record
George A. Doherty
Also filed as: DOHERTY GEORGE · DOHERTY GEORGE A
53 granted patents·59 pending applications·772 citations·filing 2000–2024
98Inventor score
Top patents by PatentIndex Score
112 records- 0198US8546399B2Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseasesBRUNCKO MILAN·Filed 2010·Granted Oct 1, 2013·100 cites·24 claims
- 0297US9174982B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2013·Granted Nov 3, 2015·38 cites·7 claims
- 0397US8586754B2BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseasesBRUNCKO MILAN·Filed 2010·Granted Nov 19, 2013·59 cites·8 claims
- 0497US8580794B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesDOHERTY GEORGE A·Filed 2010·Granted Nov 12, 2013·44 cites·3 claims
- 0597US8563735B2Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseasesBRUNCKO MILAN·Filed 2009·Granted Oct 22, 2013·72 cites·4 claims
- 0697US8557983B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesDOHERTY GEORGE A·Filed 2010·Granted Oct 15, 2013·44 cites·2 claims
- 0796US9034875B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2013·Granted May 19, 2015·19 cites·1 claims
- 0896US9029404B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2013·Granted May 12, 2015·19 cites·1 claims
- 0994US9073855B2BCL-2 selective apoptosis-inducing agents for the treatment of cancer and immune diseasesABBVIE INC·Filed 2013·Granted Jul 7, 2015·11 cites·2 claims
- 1094US9045420B2Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseasesABBVIE INC·Filed 2013·Granted Jun 2, 2015·11 cites·1 claims
- 1194US8952157B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2013·Granted Feb 10, 2015·22 cites·5 claims
- 1292US8940737B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2012·Granted Jan 27, 2015·7 cites·10 claims
- 1391US9303025B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2014·Granted Apr 5, 2016·11 cites·4 claims
- 1491US6420418B1Heterocycle amides as cell adhesion inhibitorsMERCK & CO INC·Filed 2000·Granted Jul 16, 2002·49 cites·22 claims
- 1590US9072748B2BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseasesABBVIE INC·Filed 2013·Granted Jul 7, 2015·11 cites·10 claims
- 1690US8975398B2NAMPT inhibitorsABBVIE INC·Filed 2013·Granted Mar 10, 2015·13 cites·13 claims
- 1790US7351725B2N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as Edg receptor agonistsMERCK & CO INC·Filed 2003·Granted Apr 1, 2008·40 cites·10 claims
- 1889US11964990B21,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepine bcl-2 inhibitorsABBVIE INC·Filed 2023·Granted Apr 23, 2024·1 cites·2 claims
- 1989US11633497B2Anti-c-Met antibody drug conjugatesABBVIE INC·Filed 2022·Granted Apr 25, 2023·1 cites·8 claims
- 2089US10676485B2Macrocyclic MCL-1 inhibitors and methods of useABBVIE INC·Filed 2018·Granted Jun 9, 2020·2 cites·2 claims
- 2189US9125913B2Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseasesABBVIE INC·Filed 2013·Granted Sep 8, 2015·10 cites·6 claims
- 2288US8889675B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2012·Granted Nov 18, 2014·3 cites·9 claims
- 2387US7309721B2Aminoalkylphosphonates and related compounds as Edg receptor agonistsMERCK & CO INC·Filed 2003·Granted Dec 18, 2007·37 cites·15 claims
- 2487US2024285611A1Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2023·Application pending·0 cites
- 2586US9266877B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2014·Granted Feb 23, 2016·2 cites·2 claims
- 2686US9227963B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2014·Granted Jan 5, 2016·2 cites·2 claims
- 2786US7479504B2Edg receptor agonistsMERCK & CO INC·Filed 2003·Granted Jan 20, 2009·28 cites·5 claims
- 2886US2025313572A1Macrocyclic mcl-1 inhibitors and methods of useABBVIE INC·Filed 2024·Application pending·0 cites
- 2986US2025019364A1Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2024·Application pending·0 cites
- 3084US2025177374A1BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the SameABBVIE INC·Filed 2024·Application pending·0 cites
- 3183US9187472B2NAMPT inhibitorsABBVIE INC·Filed 2013·Granted Nov 17, 2015·5 cites·1 claims
- 3283US7605171B2(3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonistsMERCK & CO INC·Filed 2004·Granted Oct 20, 2009·27 cites·15 claims
- 3383US7220734B21-(amino)indanes and (1,2-dihydro-3-amino)-benzofurans, benzothiophenes and indoles as Edg receptor agonistsMERCK & CO INC·Filed 2003·Granted May 22, 2007·19 cites·17 claims
- 3483US2024043404A1Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2023·Application pending·0 cites
- 3582US11897864B2Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2022·Granted Feb 13, 2024·0 cites·27 claims
- 3682US8044069B2Compounds as calcium channel blockersABBOTT LAB·Filed 2009·Granted Oct 25, 2011·6 cites·17 claims
- 3782US2024228509A1Macrocyclic mcl-1 inhibitors and methods of useABBVIE INC·Filed 2023·Application pending·0 cites
- 3881US8524702B2Substituted benzoazepines as toll-like receptor modulatorsHOWBERT JAMES JEFFRY·Filed 2010·Granted Sep 3, 2013·6 cites·20 claims
- 3981US2025092062A1Macrocyclic mcl-1 inhibitors and methods of useABBVIE INC·Filed 2024·Application pending·0 cites
- 4080US8304407B28-substituted benzoazepines as toll-like receptor modulatorsDOHERTY GEORGE A·Filed 2012·Granted Nov 6, 2012·5 cites·20 claims
- 4179US6943180B2Substituted N-arylsulfonyl-proline derivatives as potent cell adhesion inhibitorsMERCK & CO INC·Filed 2002·Granted Sep 13, 2005·14 cites·28 claims
- 4278US8716498B26-substituted phenoxychroman carboxylic acid derivativesARRAY BIOPHARMA INC·Filed 2013·Granted May 6, 2014·2 cites·1 claims
- 4378US8153622B28-substituted benzoazepines as toll-like receptor modulatorsDOHERTY GEORGE A·Filed 2006·Granted Apr 10, 2012·4 cites·22 claims
- 4478US2023399340A1Macrocyclic mcl-1 inhibitors and methods of useABBVIE INC·Filed 2022·Application pending·0 cites
- 4577US9877958B2Apoptosis-induced agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2016·Granted Jan 30, 2018·1 cites·16 claims
- 4677US9844547B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2015·Granted Dec 19, 2017·1 cites·10 claims
- 4777US8163738B2Aminodiazepines as toll-like receptor modulatorsDOHERTY GEORGE A·Filed 2006·Granted Apr 24, 2012·3 cites·42 claims
- 4877US2024058450A1BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the SameABBVIE INC·Filed 2022·Application pending·0 cites
- 4977US2022259226A1Macrocyclic mcl-1 inhibitors and methods of useABBVIE INC·Filed 2022·Application pending·0 cites
- 5076US9193723B2NAMPT inhibitorsABBVIE INC·Filed 2013·Granted Nov 24, 2015·2 cites·18 claims
Showing the top 50 of 112 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when George A. Doherty files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →